Introduction
============

*Chlamydia trachomatis* is the leading infectious cause of blindness worldwide. Persistent infection or recurrent infection with *C. trachomatis*, can stimulate a fibrotic immune response that leads to deposition of scar tissue on the upper tarsal conjunctiva and the development of a dry eye syndrome. The progressive development of scar tissue can lead to entropion and trachomatous trichiasis (TT), which if left untreated may result in damage to the cornea causing opacity, low vision, and blindness (Mabey et al., [@B45]). There are an estimated eight million individuals currently suffering from TT with about 1.3 million irreversibly blind as a result (Mariotti et al., [@B47]).

*Chlamydia trachomatis* is also the most common bacterial sexually transmitted infection. It is frequently asymptomatic, especially in women and can lead to sub-fertility, chronic pelvic inflammatory disease, ectopic pregnancy, and sterility (WHO, [@B71]). Although both ocular and genital chlamydial infections are treatable with antibiotics, persistent, and recurring infection is common. A licensed vaccine against *C. trachomatis* for use in the human population is not yet available despite continued efforts since the 1960s. Recent developments (reviewed by Rockey et al., [@B60]) have yielded encouraging results in some animal models; however, the development of an effective vaccine requires further understanding of the basic features of the human immune response to *C. trachomatis* infection. Indeed work in mice has suggested that chlamydial vaccine induced immunity without pathology can be achieved and this is distinct from immunity induced by infection that results in pathology (Igietseme et al., [@B36]). However in naturally exposed populations only a minority develops the pathological sequelae of infection, suggesting that the immunological features of naturally immune individuals may be equally distinct.

In animal models of infection it is well established that CD4+ T helper type 1 (Th1) cells are essential for the clearance of primary chlamydial infection (Igietseme et al., [@B36]). In particular, IFNγ plays an important role in the clearance of chlamydial infection. In mice and in humans its production is associated with protection from re-infection (Wang et al., [@B70]; Cohen et al., [@B13]). However, uncontrolled inflammatory responses, in part driven by IFNγ production, result in pathology. Regulatory T cells (Tregs), induction of regulatory cytokines such as IL-10 or the activation of type 2 (Th2) responses counteract the inflammatory environment and contribute to restoring homeostasis (Yang et al., [@B74]; Wang et al., [@B67]). Conversely unchecked type 2 responses are frequently associated with chronic inflammation and infection (Wynn, [@B72]) and hampering Th2 responses have been implicated in chlamydial infections and induced disease (Holland et al., [@B30], [@B29]; Gondek et al., [@B23]). In addition some immune mediated fibrotic diseases, such as schistosomula induced hepatic fibrosis, are also dominated by Th2-cytokine responses (Chiaramonte et al., [@B12]). The pathogenic changes observed at the site of infection in chlamydial genital and ocular disease are also due to development of fibrotic tissue yet convincing evidence of a significant role for polar CD4+ Th2 responses or alternative macrophage activation are lacking (Holland et al., [@B31]; Natividad et al., [@B51]). Many groups have now demonstrated the important role of immunoregulatory subsets of CD4+ T cells in preventing immune damage during viral, bacterial, and parasitic infections, and specifically in persistent infections at mucosal surfaces (Maloy and Powrie, [@B46]; Belkaid and Tarbell, [@B5]) but these have not been extensively studied in human chlamydial disease.

One subset of CD4+ T cells that has key functions in immune homeostasis are Tregs (CD4+CD25+FOXP3+). The regulatory function of these natural and adaptive Tregs may be mediated by production of TGF-β and IL-10 or by cognate interaction (Hori et al., [@B32]; Fontenot et al., [@B21]). Antigen-specific IL-10 secreting type-1 T regulatory cells (T~R~1) which do not express *FOXP3* have also been described *in vivo* following chronic antigenic stimulation (Vieira et al., [@B66]), and develop in parallel with Th1 cells in several chronic infectious diseases (McGuirk et al., [@B49]). Murine studies have established that *FOXP3* + regulatory cells can secrete both IFNγ and IL-10 (Stock et al., [@B62]) and in humans regulatory function can also be exerted via perforin dependent lysis (Grossman et al., [@B26]). Thus, although most work has focused on cells with a classic Treg phenotype (CD4+CD25+FOXP3+), cells from CD4+CD25−, CD8+, and NKT subsets can all exert regulatory function (Jiang and Chess, [@B38]). There is also evidence that CD4+ Th1 cells can exhibit self-regulatory properties and cytokine profiles, obviating the need to explain disease in terms of a separate regulatory class of T cells (Anderson et al., [@B1]; Jankovic et al., [@B37]).

We have previously demonstrated a relative *Chlamydia*-specific hypo-responsiveness associated with chronic ocular infection (Holland et al., [@B30]; Bailey et al., [@B3]), and described imbalances in antigen-specific secretion of both IL-10 and IFNγ in cultured peripheral blood mononuclear cell (PBMC) from scarred subjects (Holland et al., [@B29]). We have also found that IFNγ, IL-10, and perforin expression in the conjunctiva is associated with the clinical signs of active trachoma (Burton et al., [@B9]); that susceptibility to scarring sequelae is affected by haplotypic variation at the IL-10 locus (Natividad et al., [@B53], [@B52]), that contributes to variation in IL-10 expression; and that the expression of *FOXP3* is up-regulated in individuals who have recently resolved ocular *C. trachomatis* infection (Faal et al., [@B17]).

In animal models of viral ocular infection, several groups have identified an important role for Tregs in modulating the severity of disease (Suvas et al., [@B63]; Nesburn et al., [@B54]). Aside from FOXP3, other potential makers of regulatory T cells have been identified in the search to phenotypically define Tregs. Most commonly the relative expression of the IL-7 receptor (CD127) is used as a fourth surface marker (Finney et al., [@B19]), the low expression of which is regarded as further evidence of Tregs. Two other common markers with demonstrated independent down regulatory properties are Cytotoxic T Lymphocyte Antigen 4 (CTLA4) and Glucocorticoid-induced tumor necrosis factor-receptor related protein (GITR) both of which have been linked to the suppressive mechanism of Tregs (Zheng et al., [@B76]; Nocentini and Riccardi, [@B55]). Moreover, in rabbits with ocular HSV infection, cells in the conjunctiva, which expressed high levels of FOXP3, GITR, and CTLA4, were effectively able to suppress the effector function of HSV-specific CD4+ and CD8+ T cells (Nesburn et al., [@B54]).

In this study we compared the *in vitro* immune responses of individuals with TT and controls with normal eyes from trachoma endemic communities, since we expected that immune responses from these individuals would be the most polar. We investigated the immune responsiveness of several chlamydial antigens that had not previously been measured in individuals from trachoma endemic communities. Cytokine levels in supernatants from proliferation assays were quantified for IL-5, IL-10, IL-12p70, IL-13, IFNγ, and TNFα. Immune responses were also assessed using flow cytometry, where cells were stained for IFNγ and IL-10, as well as Treg cell markers FOXP3, CTLA4, and GITR. To investigate which cells were the major sources of IFNγ, we further stained for markers that included CD8 and CD3−CD56+ cells in PBMC isolated from young and adult individuals from the same trachoma endemic environment.

Materials and Methods
=====================

Study participants
------------------

Informed consent was obtained from all study participants. Participants were recruited from rural and semi-urban areas within the Western Region and the Lower river regions (LRR) of The Gambia. Trachoma was graded using the WHO simplified grading system by a single experienced field supervisor. Forty-two subjects with TT (more than one eyelash touching the globe of the eye) were identified. For each TT case an age, sex, and location matched control subject with normal eyes that was not a member of the same family was also recruited. Participants were age matched within 10 years. In a standardized manner, an ocular swab from the everted tarsal conjunctiva of each participant was collected into RNA*later*^®^ (Ambion Ltd) for the later isolation of proteins and nucleic acids. For the *in vitro* study of natural killer (NK) cell responsiveness, five healthy participants from three different age groups (2--5; 15--25; \>35 years) from trachoma endemic communities in the West Kiang District of LRR were recruited. Historical exposure to ocular infection in these districts was expected to be high since structured surveys as part of a national trachoma control program identified this district as requiring mass drug treatment. As a result, these communities were treated with three annual rounds of oral azithromycin, completed in 2009 as per WHO guidelines for community control strategies. The joint Scientific and Ethics Committee of the Gambian government and the Medical Research Council Laboratories approved each study (applications L2006.10 and SCC1201). In addition the ethics committee of the LSHTM also approved the studies. All study participants outside of community trachoma control programs were offered treatment according to national eye care program guidelines.

Proliferation assays
--------------------

Venous blood (20 ml) was collected into tubes containing 300 units of sterile, preservative-free sodium heparin. After the removal of 2.5 ml of blood for whole blood cultures the PBMCs were isolated from the remaining blood by centrifugation over Lymphoprep (Axis-Shield Ltd, Kimbolton, UK) as described previously (Holland et al., [@B29]). Plasma was harvested by collection from above the PBMC layer and stored at −30°C for later use in enzyme-linked immunosorbent assays (ELISA) to estimate the anti-chlamydial antibody titer. PBMCs were co-incubated for 7 days with 5 μg/ml of each antigen (Pokeweed mitogen, PWM; Purified protein derivative, PPD) of *Mycobacterium tuberculosis* strain Rv37 and the following *C. trachomatis* antigens; Serovar A (strain SA1) elementary bodies (EBs), major outer membrane protein (MOMP), Enolase, polymorphic outer membrane protein (Pmp) D, PmpG, outer membrane protein (Omp) 2. On day six, 100 μl of culture supernatant was removed from each well without disturbing the cell pellet and 1 μCi/well ^3^H-thymidine added for the last 18 h of culture. The culture supernatant was frozen at −30°C until tested by multiplex bead array for cytokines. ^3^H-thymidine incorporation was estimated using liquid scintillation counting (Micro-beta, Wallac, Turku, Finland). Results were expressed as log~10~ stimulation indices (SI), which were calculated as described by Bennett and Riley ([@B6]) using the geometric mean of the triplicate counts per minute (CPM) for the test antigen/CPM (geometric mean) of triplicate wells that only received cells and RPMI.

Cytokine detection
------------------

The triplicate wells of day six supernatants from microtiter plates were pooled and 25 μl used in a six-plex (IL-5, IL-10, IL-12p70, IL-13, IFNγ, and TNFα) cytokine assay (Bio-Rad, United Kingdom) according to the manufacturer\'s instructions. The plates were then read using a Bio-plex instrument (Bio-Rad, UK). Unknown samples were quantified by reading standard curves prepared for each of the cytokines under study. Lower and upper limits of detection were dependent on assay performance. Any samples with cytokine levels that were outside of the working range of each assay were reported as under or over the detection limit and for the purposes of analysis were given a value equal to the minimum or maximum detectable level.

Antibody staining and facs analysis
-----------------------------------

Five hundred microliters of whole blood was co-stimulated with 10 μg/ml of FastImmune™ \[CD28/CD49d co-stimulatory reagent (BD Biosciences)\] and incubated with 5 μg/ml of whole Ct EB or *Staphylococcus aureus* Enterotoxin B (SEB) for 48 h. Cultures stimulated with FastImmune™ alone served as controls. BD GolgiPlug™ (Brefeldin A; BD Biosciences) was added for the last 18 h of culture at 1 μg/ml. Cells were harvested by centrifugation followed by lysis of red blood cells and further washing in serum free RPMI by centrifugation. When required, PBMC were permeabilized for intracellular staining. The following antibodies were used: CD4-PerCP (SK3), CD25-FITC (M-A251), IFNγ-FITC (4S.B3), IL-10-PE (JES3-19F1) and CTLA4-PE (BNI3) CD69-APC (FN50; BD Pharmingen), FOXP3-APC (PCH101; eBiosciences), and GITR-PE (110416; R&D Systems). Samples were then examined using a FACS Caliber flow cytometer (Becton, Dickinson and Company, NJ, USA) and the data collected using CellQuest-Pro. Files were further analyzed using FlowJo software (Treestar, OR, USA).

Cell surface and intracellular staining for NK cells
----------------------------------------------------

Surface and intracellular staining was performed as described previously (Horowitz et al., [@B33],[@B34]). Briefly 4 × 10^5^ PBMC were incubated for 24 h with 10 μg/ml EBs. As a positive control rIL-12/IL-18 were added to separate cultures. Abs used were as follows: CD69 PE (CH/4; BD Pharmingen), CD56 PE (N901), CD56 APC (N901; both Beckman Coulter, Fullerton, CA, USA), CD56 PE-Cy7 (B159), CD3-PerCP (SK7), CD4 APC-Cy7 (RPA-T4), CD4 PE (RPA-T4), CD8 PE (SK1), CD3 PE-Texas Red (S4.1) CD107a (LAMP-1) biotin (H4A3; Caltag/Invitrogen), CD8 Pacific Blue (LT8; eBiosciences, San Diego, CA, USA), and IFNγ FITC (D9D10; Ab Serotec). For CD107a staining antibody and GolgiPlug™ were added to the cultures for the last 4 h of stimulation when they were washed and permeabilized. The remaining cocktail of antibodies was then added staining both surface and intracellular antigens. Samples were then examined using a Dakocytomation CyAn flow cytometer (Beckman Coulter, Fullerton, CA, USA) and the data collected using Summit FCS 4.3 software. Files were further analyzed using FlowJo (Treestar, OR, USA).

Isolation of DNA from ocular swabs
----------------------------------

DNA was isolated from ocular swabs using Qiagen RNeasy micro kits and DNA mini kits as described elsewhere (Holland et al., [@B31]). The presence of *C. trachomatis* was then tested using CT/NG by Amplicor (Roche) as described previously (Holland et al., [@B31]). Sample integrity and quality for each ocular swab was confirmed by performing PCR on genomic DNA using primers for human-specific hypervariable 1 (HV1) D-loop region mitochondrial DNA as described previously (Harding-Esch et al., [@B27]).

Serology
--------

Plasma antibody titrations were performed using purified serovar A EBs immobilized on ELISA microtiter plates as described previously (Wang et al., [@B68], [@B69]).

Statistical analysis
--------------------

Statistical analysis was performed using the statistical analysis tool in GraphPad Prism 5 software (GraphPad Software, Inc, La Jolla, CA, USA). A paired Student\'s *t*-test was used for combined data of cases and controls when compared to background controls. When comparing the response of matched cases and controls an adaptation of the Mann--Whitney distribution-free paired test was used (Wilcoxon signed rank). For the simultaneous comparison of three age groups we used a non-parametric ANOVA (GraphPad Prism) which is a omnibus Kruskal--Wallis test progressing to *post hoc* testing of simultaneous pairwise comparisons using Dunn\'s Test if the overall *P*-value \< 0.05. Both Kruskal--Wallis and Dunn\'s Test are distribution-free tests of significance.

Results
=======

Study participants
------------------

The basic study participant details from each section of the study are described in Table [1](#T1){ref-type="table"}. Forty-two case--control pairs were used in the lymphocyte proliferation assays. Up to 17 of these case--control pairs were studied using FACS analysis and multiplex bead arrays for cytokines. Approximately 2/3 of the case--control pairs were from females (27/42) and the median age was 58 years. All ocular swabs for these samples were positive for human mitochondrial DNA and negative by CT/NG Amplicor for current ocular infection with *C. trachomatis*. Plasma anti-*C. trachomatis* antibody levels were not significantly different between the clinical groups and all sera were positive compared to plasma from immunologically naïve individuals.

###### 

**Study participant demographics and Ct antibody titers**.

  ------------------------------------- ------------------------------------ ------------------------------------ -------------------------------------- -- --
  **PBMC PROLIFERATION SAMPLES**                                                                                                                            
                                        **Cases (*n* = 42)**                                                      **Controls (*n* = 42)**                   
  Age (range) in years                  60 (30--85)                                                               57 (30--80)                               
  Sex                                                                                                                                                       
     Male                               15                                                                        15                                        
     Female                             27                                                                        27                                        
  Anti-Ct (serovar A) antibody titer    1 × 10^4^ (\<1 × 10^3^--2 × 10^4^)                                        7.5 × 10^3^ (\<1 × 10^3^--2 × 10^4^)      
  CT/NG Amplicor                        0                                                                         0                                         
  **FLOW CYTOMETRY AND BIO-PLEX**                                                                                                                           
                                        **Cases (*n* = 17)**                                                      **Controls (*n* = 17)**                   
  Age (range) in years                  58 (35--70)                                                               54 (31--75)                               
  Sex                                                                                                                                                       
     Male                               6                                                                         6                                         
     Female                             11                                                                        11                                        
  Anti-Ct antibody titer (1/×; range)   1 × 10^4^ (\<1 × 10^3^--2 × 10^4^)                                        1 × 10^4^ (\<1 × 10^3^--2 × 10^4^)        
  CT/NG Amplicor (*n* = no. positive)   0                                                                         0                                         
  **NK PBMC FLOW CYTOMETRY**                                                                                                                                
                                        \<**5 years (*n* = 5)**              \<**25 years (*n* = 5)**             \>**35 years (*n* = 5)**                  
  Age (range)                           3 (2--5)                             17 (16--25)                          67 (37--72)                               
  Sex                                                                                                                                                       
     Male                               3                                    3                                    2                                         
     Female                             2                                    2                                    3                                         
  Anti-Ct (serovar A) antibody titer    1 × 10^3^                            1 × 10^3^ (\<1 × 10^3^--2 × 10^4^)   1 × 10^4^ (\<1 × 10^3^--2 × 10^4^)        
  No. with clinical signs               0                                    0                                    0                                         
  No. seropositive                      2                                    5                                    5                                         
  CT/NG Amplicor (*n* = no. positive)   n.t.                                 n.t.                                 n.t.                                      
  ------------------------------------- ------------------------------------ ------------------------------------ -------------------------------------- -- --

Lymphocyte proliferative responses to *C. trachomatis* antigens
---------------------------------------------------------------

To determine whether the proliferative response of TT cases differed from that of the controls we studied the responses to chlamydial EBs and five recombinant antigens (Table [2](#T2){ref-type="table"}). PWM was used as a positive control for the stimulation of T and B cells. We considered a SI \> 2 as a significant proliferative response. Enolase, PmpD, PmpG, and Omp2, induced a pathogen-specific proliferative response that was above background and comparable to proliferation induced by stimulation with EBs. In general and as a trend, responses were higher in cases compared to controls; however, no statistically significant differences were found between TT cases and controls (Figure [1](#F1){ref-type="fig"}).

###### 

**Summary of recombinant antigens used**.

  Serovar D locus-tag (NC000117)   Name      Antigen details (kDa)                                                          Serovar origin   DNA insert fragment size (bp)        Product size by SDS--PAGE (kDa)   Production of original expression clone                           Fusion protein type   Recombinant expression and purification                                                     Publications (cellular responses only)
  -------------------------------- --------- ------------------------------------------------------------------------------ ---------------- ------------------------------------ --------------------------------- ----------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------- ----------------------------------------
  CT812                            PmpD      Polymorphic outer membrane protein (polymorphic family of 9 genes A--I; 160)   L2               2.024 kb (690--2714 gene fragment)   74                                Prof. Hill Gaston and Dr. Jane Goodall, University of Cambridge   His-tag               pPET/ProBond^®^                                                                             Goodall et al. ([@B25])
  CT681                            MOMP      Major outer membrane protein (40)                                              L1               1.6 kb (285--1182 gene fragment)     33                                Prof. Ian Clarke, University of Southampton                       B-gal                 Induced insoluble inclusions purified by centrifugation resuspended in octylglucoside/DTT   Holland et al. ([@B30])
  CT871                            PmpG      Polymorphic outer membrane protein (107)                                       A                1.509 kb (127--1726 gene fragment)   61                                Dr. Mark Felton, LSHTM                                            His-tag               pPET/ProBond^®^                                                                             Felton ([@B18])
  CT587                            Enolase   Phosphopyruvate hydratase (enolase family; 45)                                 L2               1.274 kb (full length)               45                                Prof. Hill Gaston and Dr. Jane Goodall, University of Cambridge   His-tag               pPET/ProBond^®^                                                                             Goodall et al. ([@B25])
  CT443                            Omp2      Cysteine rich outer membrane protein (60)                                      L2               1.65 kb (700--2350 gene fragment)    60                                Prof. Hill Gaston and Dr. Jane Goodall, University of Cambridge   His-tag               pPET/ProBond^®^                                                                             Goodall et al. ([@B24])
                                                                                                                                                                                                                                                                                                                                                                                                        

![**Trachomatous trichiasis cases do not differ in proliferative responses to ***Chlamydia trachomatis*** antigens compared to controls**. PBMCs log~10~ stimulation index (test antigen c.p.m/non-stimulated c.p.m) were calculated after 6 days of stimulation with PWM or chlamydial antigens EBs, MOMP, Enolase, PmpD, PmpG, Omp2. Trichiasis cases (•) and disease free endemic controls (○). Paired students *t*-test was performed on each group (up to 42 pairs). The dashed line represents stimulation index = 2. All responses above this dashed line were considered above background. Each antigen induced a statistically significant response above background. No statistical significance was detected between proliferative responses of the clinical groups to any chlamydial antigen. Analysis based on the proportion of responder (SI \> 2) versus non-responder (SI \< 2) also found that there were no differences evident between the clinical groups.](fmicb-02-00010-g001){#F1}

Stimulation of cytokine responses by *C. trachomatis* antigens
--------------------------------------------------------------

Day six supernatants from proliferation assays were collected and assessed for the presence of IL-5, IL-10, IL-12p70, IL-13, IFNγ, and TNFα cytokines. All antigens tested were able to elicit an IL-10, IL-12p70, IFNγ, and TNFα cytokine response that was significantly above background. Few antigens, however, were able to stimulate IL-5 or IL-13 production. The levels of antigen-specific cytokine production are summarized in Figure [2](#F2){ref-type="fig"}. EB stimulated responses were significantly above background for IL-10, IFNγ, and TNFα in both TT cases and controls. However, these cytokine profiles did not correlate with disease status (Figure [2](#F2){ref-type="fig"}). Taken together the cytokine and proliferation data show that peripheral blood proliferative responses and cytokine production profiles are not significantly different between participants with and without TT.

![**Chlamydial antigens induce cytokine responses that are significantly above responses of cultures in culture medium alone, however, the levels of cytokine production are not statistically different between diseased and non-diseased individuals**. Each plot represents IL-5, IL-10, IL-12p70, IL-13, IFNγ and TNFα production in response to stimulation with *Ct* EBs, MOMP, Enolase, PmpD, PmpG, and Omp2. Responses from TT cases and controls are depicted as shaded and non-shaded box and whisker plots respectively.](fmicb-02-00010-g002){#F2}

CD4+CD25+FOXP3+ cells are increased following stimulation with *C. trachomatis* antigens
----------------------------------------------------------------------------------------

We investigated whether immune responses of TT patients differ in regulatory phenotypic markers when stimulated by chlamydial antigens compared to their respective controls. Whole blood from 17 case--control pairs (*n* = 34) was stimulated with *C. trachomatis* EBs for 48 h and stained with antibodies which in combination identify Tregs (CD4+CD25+FOXP3+). FOXP3+ cells were largely contained in the CD4+CD25+ population, where the CD25+ population was continuous and no distinction was made between CD25^hi^+ and CD25^lo^+ cells. EBs were particularly effective at inducing Tregs, relative to those cells that received co-stimulation alone (Figure [3](#F3){ref-type="fig"}A). Figure [3](#F3){ref-type="fig"}B shows an example of the flow cytometry multilevel gating strategy used on each sample. CTLA4 and GITR were also used as additional surface markers of Treg activity. Stimulation with chlamydial EBs was effective in inducing the up-regulation of CTLA4 and GITR (Figure [3](#F3){ref-type="fig"}B). However, when these phenotypic markers of regulatory activity were compared between TT cases and their controls, no statistical difference was found (Figure [3](#F3){ref-type="fig"}C). As a general trend CD4+CD25+FOXP3+ cells and CD4+GITR+ cells were higher in TT cases to all chlamydial antigens tested (additional data not shown). Similarly, no difference was detected in the frequency of CD4+FOXP3+ or CD4+CD25+ cells between cases and controls. Since no differences in regulatory cells were apparent we also used the CD4+CD25+FOXP3− population as an indicator of effector cell responses and found that the population frequencies of these cells were equivalent between cases and controls stimulated with EBs (Figure [3](#F3){ref-type="fig"}C).

![**Representative FACS plots of whole blood cultured for 48 h with co-stimulatory molecules CD28/CD49d (A)** or CD28/CD49d and chlamydial elementary bodies **(B)** are shown to demonstrate the gating strategy used to enumerate the percentage of Tregs. FOXP3+ cells were gated within the population of CD4+CD25+ cells. The CD25+ population was taken as continuous (CD25^hi^ and CD25^lo^ expressing cells were not differentiated). CD4+ effector cells were identified as the CD4+CD25+FOXP3− population. **(C)** Responses of trichiasis cases (*n* = 17) and endemic controls (*n* = 17) are represented as a stimulation ratio (i.e., percentage of CD4+CTLA4+ cells induced by EB stimulation/percentage of CD4+CTLA4+ induced by co-stimulation alone). Tregs and CD4+GITR+ cells were higher in trichiasis cases but there were no statistically significant differences between cases and controls in either regulatory or effectorT cell populations.](fmicb-02-00010-g003){#F3}

Activated lymphocytes produce IFNγ and IL-10 in response to *C. trachomatis* elementary bodies
----------------------------------------------------------------------------------------------

Whole blood was stimulated as previously described and stained for CD69, a marker of early activation, in addition to CD4, intracellular IFNγ and IL-10. Stimulation with EBs showed a marked increase in CD69 expression and a higher frequency of IFNγ and IL-10 producing cells. Figure [4](#F4){ref-type="fig"}A shows the FACS analysis gating procedure used to examine IFNγ and IL-10 production from CD4+ T cells and total PBMC. Despite the induction of CD69 on CD4+ cells and the production of IFNγ and IL-10, effector T cell responses were not significantly different between cases and controls (Figure [4](#F4){ref-type="fig"}C).

![**CD4+ cells are not the primary source of IFNγ following stimulation with EBs**. **(A)** Representative FACS plots of whole blood cultured for 48 h with EBs and co-stimulatory CD28/CD49d demonstrate the gating strategy used to distinguish between total and CD4+ IFNγ producing cells, as well as total and CD4+ IL-10 producing cells. **(B)** Percentage of total IFNγ+, CD69+, and IL-10 producing cells is significantly higher than the percentage of CD4+ IFNγ+, CD4+CD69+, and CD4+IL-10+ cells in all trichiasis cases and controls (*n* = 34), indicating that CD4+ T cells are not the only source of IFNγ, IL-10, and activated cells. **(C)** Responses from trichiasis cases (*n* = 17) and controls (*n* = 17) represented as a stimulation ratio (as in Figure [3](#F3){ref-type="fig"}). The ratio of CD4+ activated (CD69+) or IFNγ+/IL-10+ cells are slightly higher in the control group but the difference is not significantly different.](fmicb-02-00010-g004){#F4}

CD4 + cells are not the major IFNγ producing cells in response to stimulation with *C. trachomatis* elementary bodies
---------------------------------------------------------------------------------------------------------------------

To assess if CD4+ T cells encapsulated the observed increases in the percentage of CD69, IFNγ, and IL-10 in the total stimulated population of peripheral blood lymphocytes we examined the percentage of each of these in the CD4+ compartment and the total PBMC compartment. We found that on average less than half of the cells that were producing IFNγ, IL-10, or expressed CD69 were also CD4+ (Figure [4](#F4){ref-type="fig"}B). To establish which cells were responsible for IFNγ production we tested PBMC from individuals exposed to ocular infection but without current signs of trachoma. Five individuals were selected from three different age ranges. This strategy was chosen because we had demonstrated that endemic controls had significant responses to EBs above those observed with co-stimulation alone, but that these were not significantly different between case and control participants. Figure [5](#F5){ref-type="fig"}A shows representative FACS plots and flow diagrams of the gating and staining protocols used. There was some natural variation with age in the total percentage of NK cells (CD3−CD56+ cells) and of CD8+ T cells. The percentage of CD4+ T cells did not appear to vary with age (Figure [5](#F5){ref-type="fig"}B). We found that in the first 24 h of *in vitro* stimulation, EBs induced IFNγ in CD4+, CD8+, and NK cells. The percentage of IFNγ producing cells in response to stimulation with EB significantly increased with age and adults over 35 years of age demonstrated the highest levels. The percentage of CD4+ IFNγ+, although increased, did not appear to vary with age and the overall levels were approximately 4× lower. Interestingly, CD8+ IFNγ+ T cells were highest in the first two age groups though the overall levels were lower than those observed for NK (CD3−CD56+) cells (Figure [5](#F5){ref-type="fig"}C). Further confirmation that EB stimulation resulted in stimulation of NK cells that increased with age was seen by increasing levels of CD107a+ NK cells, whereas CD8+CD107a+ T cells decreased with age or were almost absent. As expected the CD4+ T cells expressed negligible levels of CD107a (Figure [5](#F5){ref-type="fig"}D). Figures [5](#F5){ref-type="fig"}C, D further show that stimulation with EB leads to increases in the percentages of both IFNγ and CD107a expressing NK cells (up to 40% of NK cells express CD107a when stimulated by EB in adults over 35 years of age) compared to control cultures with culture medium alone and that in each case the difference and magnitude increases with age.

![**CD3−CD56+ natural killer (NK) cells are a major source of IFNγ in response to EB stimulation that increases with age**. PBMC from healthy individuals ranging in age from 2 to 5 years (*n* = 5), 15--25 years (*n* = 5), and \>35 years (*n* = 5) were stimulated for 24 h with EB. **(A)** Representative FACS plots demonstrate the gating strategy used to define populations of CD4+ and CD8+ T cells and NK cells. NK cells (CD3−CD56+) were gated from CD3+ T cells. The CD3+ T cells were then further sub-divided based on CD4+ or CD8+ expression. **(B)** Cell percentages in each age group demonstrate the natural variation of CD8+ T and NK cell levels, whereas CD4+ T cell levels do not appear to vary with age. **(C)** The percentage of NK cells producing IFNγ significantly increased with age, while the percentage of CD8+ IFNγ+ cells significantly decreased in the \>35 years age group. The percentage of CD4+ IFNγ+ did not differ among the different age groups. **(D)** The percentage of CD107a+ NK cells significantly increased with age, whereas levels of CD107a expression in CD8+ T cells did not differ with age. CD4+ T cells expressed negligible levels of CD107a.](fmicb-02-00010-g005){#F5}

Discussion
==========

Both TT cases and controls had lymphoproliferative responses that were above background when stimulated with EBs, Enolase, PmpD, PmpG, and Omp2 antigens. Responses to some of these antigens have been investigated as putative vaccine candidates (Coler et al., [@B14]; Goodall et al., [@B24],[@B25]) and studied in human infection. More recently, a number of chlamydial antigens such as LcrE (CPn0324/CT089) and chlamydial protease-like activating factor (CPAF/CT858) have been proposed as potential vaccine candidates and their responsiveness has been tested in animals and humans (Olsen et al., [@B58], [@B57], [@B59]; Thorpe et al., [@B64]; Barker et al., [@B4]; Follmann et al., [@B20]). Although most of the TT study participants were able to elicit proliferative responses to the chlamydial antigens, the degree of proliferation was not significantly different between individuals with severe scarring disease and controls without disease. As a general trend responses to each antigen were higher in cases with TT, in contrast to our previous findings (Holland et al., [@B30], [@B29]). However, in previous studies higher proportions of individuals with trachomatous scarring were still infected with *C. trachomatis* and were at earlier stages of disease, where *C. trachomatis* driven fibrotic responses could still be progressing. We also previously found that serum antibody responses in those with trachomatous scarring were higher compared to controls whereas in this cohort *C. trachomatis* serovar A antibody responses were equal between the groups. This suggested that both groups of individuals had experienced similar levels of exposure to ocular infection and that there had been little recent infection. This changing environment could explain why we did not detect any significant differences compared with our own previous findings (Harding-Esch et al., [@B28]).

Although MOMP constitutes up to 60% of an EB it nevertheless contains a significant proportion of the total antigenic repertoire (Wang et al., [@B69]). It is the most abundant surface exposed protein of EBs, is highly conserved across *C. trachomatis* serovars containing a large number of T cell specific epitopes (Kim and DeMars, [@B41]; Nunes et al., [@B56]) and anti-MOMP antibodies have been shown to neutralize *C. trachomatis in vitro* (Cotter et al., [@B15]). Because of these properties it has been widely studied as a putative vaccine candidate (Zhang et al., [@B75]). More recently native MOMP (nMOMP) has been used to immunize monkeys and successfully induced high titers of neutralizing antibodies that reduced the infectious ocular burden within the first 2 weeks of infection. Despite the promising results nMOMP immunization had no lasting effects on the course of clinical disease or burden and duration of infection (Kari et al., [@B39]). In our experiments MOMP induced only weak responses in the majority of individuals. Antibodies specific to PmpD have also been shown to neutralize *C. trachomatis in vitro* regardless of serotype (Crane et al., [@B16]), and Omp2 has been shown to be recognized by *Chlamydia*-specific human CD8+ T cells (Gervassi et al., [@B22]). PmpG which is part of the outer membrane complex and may be involved in the invasion of the host cell by *C. trachomatis* was also tested. Each of these antigens induced responses but these were not significantly different between cases and controls. Thus far, with the exception of MOMP and hsp60, no other antigens have been evaluated by measuring cell mediated immune responses in individuals with trachoma. Skwor et al. ([@B61]) have tested human tear fluid for antibody reactivity to a number of antigens (cHSP60, CPAF, and CT795) and found that IgG responses to CPAF were associated with TT cases and responses to all three antigens were elevated during inflammation, but it remains unclear how this might relate to cellular responses and requires further investigation.

Interleukin-10 and IFNγ have been extensively studied in mice and humans with respect to chlamydial infection and IL-10 has been found to be associated with the persistence of infection, while IFNγ has been linked to its resolution (reviewed in Yang, [@B73]). One study using IFNγ knockout mice infected with *C. muridarum* found that production of IL-5 was elevated and correlated with more severe disease (Wang et al., [@B70]). Another study found that when murine dendritic cells were infected with *C. trachomatis*, the subsequent production of IL-12 and TNFα correlated with containment of the bacteria (Knight et al., [@B42]). Furthermore, studies have shown that mice infected with *C. muridarum* that received CD11c+ CD8α+ cells had increased amounts of proinflammatory cytokines such as IFNγ, TNFα, and IL-12 and decreased production of the Th2 cytokines IL-4, IL-5, and IL-13, which correlated with protection against infection. Our results show that in peripheral blood of individuals exposed to *C. trachomatis*, most chlamydial antigens tested were able to produce above background levels of IL-10, IL-12, IFNγ, and TNFα cytokines after 6 days of culture. Only PmpD and Enolase were able to stimulate IL-5 and IL-13 cytokine responses respectively. However, there were no clear indications that any particular antigen or cytokine profile was significantly different between cases and controls. This suggests that a larger population study is required with follow-up and repeat testing, or that the methods employed *in vitro* are not sufficiently sensitive to detect differences in these particular cytokines.

Whilst the roles of IL-10 and IFNγ have been intensively studied in chlamydial disease, there has been little investigation of regulatory T cells in mediating the response to *C. trachomatis*. Our results show that Tregs (CD4+CD25+FOXP3+) and the co-stimulatory surface markers with inhibitory or regulatory functions (CTLA4 and GITR) are up-regulated in response to stimulation with chlamydial EBs. We also found higher levels of CD4+CD25+FOXP3+ and CD4+GITR+ T cells in TT cases compared to controls (although these differences were not statistically significant). Other authors have suggested that the CD4+CD25+FOXP3− can also represent an effector population (Burl et al., [@B7]); whilst these were increased over co-stimulation alone by stimulation with EB, the levels were not significantly different between TT cases and unaffected controls. Interestingly, we found that IFNγ produced in response to *C. trachomatis* EB was not exclusive to CD4+ lymphocytes, and the *in vitro* nature of the stimulation with non-viable EBs would not efficiently favor stimulation of CD8+ T cells. Given that \<50% of the total IFNγ production appeared to be from CD4+ T cells, we investigated using flow cytometry which cells were responsible for the early IFNγ production. We found that even with a restricted sample size and therefore statistical power, CD3−CD56+ NK cells were a major source of very early IFNγ production (within the first 18 h of *in vitro* restimulation). Since the magnitude of this response increased with age and the frequency and duration of trachoma decrease with age (Bailey et al., [@B2]; Faal et al., [@B17]), it is possible that these cells play a significant role in ocular disease and infection. Such responses are not unique and are in line with those observed for responses following vaccination or as a result of protozoan or viral infection (Horowitz and Riley, [@B35]; Horowitz et al., [@B33],[@B34]; McCall et al., [@B48]). Interestingly, in subjects with active trachoma and infection, host gene transcriptional profiles in the conjunctiva suggest a previously unappreciated role for NK cells (Natividad et al., [@B51]). These initial *in vitro* experiments suggest that NK or NK-like cells are rapidly induced by EB and supports the suggestion that lymphocytes other than CD4+ T cells contribute a significant proportion of IFNγ in the periphery. EB stimulation also leads to the early activation of other non-CD4+ T cells along with IL-10 production. We did not investigate the phenotypes of the cells that are activated or produce IL-10 and this warrants further more detailed investigation. Some *in vitro* studies have suggested that stimulated T cells rapidly acquire CD56 when strongly stimulated through the CD3/TCR complex with additional IL-2 (Kelly-Rogers et al., [@B40]) and that the phenotypic profile of NK cells is heterogeneous. Since we stained for both surface and internalized CD3 to identify the classical NK cell population (CD3−CD56+; Meier et al., [@B50]; Titanji et al., [@B65]; Li et al., [@B43]; Linn et al., [@B44]) we exclude this possibility as an *in vitro* artifact and suggest that the interaction with antigen-experienced T cells should be investigated further in response to chlamydial infection.

The onset of TT usually occurs well into adulthood and previous studies have revealed that *C. trachomatis* is rarely detected in the conjunctiva at that point (Burton et al., [@B8]). Intriguingly, TT cases continue to progress toward more severe trichiasis and eventually blindness despite their peripheral immune response being comparable to that of individuals with equal exposure to infection but without the clinical signs or sequelae of trachoma. This would suggest that adaptive T cell memory responses in the periphery do not reflect clinical disease status and that other factors such as innate inflammatory responses involving polymorphs (such as neutrophils) and host epithelial cells, continue to drive fibrosis or recurrent trichiasis. This is supported by several previous studies linking conjunctival gene expression and trichiasis (Burton et al., [@B10], [@B11]; Holland et al., [@B31]). Other factors such as the compromised ocular surface and secondary bacterial infection also contribute to continued inflammation and disease. Thorough sampling of the immune response at the site of infection and a more in-depth examination of the interaction of adaptive T cell responses and NK cell responses may help further probe the mechanisms of immunopathogenesisof trachoma.
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